羟氯喹相关不良事件的年龄差异:基于FAERS的药物警戒研究
AIMS: This real-world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004-2024) to characterize age-related disparities in hydroxychloroquine (HCQ)-associated adverse events (AEs), addressing gaps in age-stratified risk assessment.…
要点
- 儿童羟氯喹不良事件中位发生时间为9.5天,早于老年人群的19天。
- 儿童特异性信号包括COVID-19相关心脏毒性(ROR=3.26)和低钾血症并发症(ROR=25.77)。
- 儿童风险轨迹呈恒定 hazard 特征(α=0.52,β=46.68),老年呈累积上升趋势(α=0.40,β=93.66)。
核心结论
- 羟氯喹相关不良事件谱、时间动态和风险演变存在显著年龄相关差异,需建立年龄分层药物警戒框架。
- 儿童特异性心脏毒性和代谢风险以及老年特异性累积毒性模式要求定制化治疗监测策略。
主要发现
- 儿童不良事件发生显著更早,中位时间为9.5天,而老年人群为19天。
- Weibull形状参数显示儿童风险轨迹为恒定 hazard(α=0.52,β=46.68),老年为上升风险(α=0.40,β=93.66)。
临床怎么用
- 对儿童使用羟氯喹时应加强早期(9.5天左右)心脏和电解质监测。
- 对老年患者应关注长期累积毒性风险,制定持续监测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This real-world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004-2024) to characterize age-related disparities in hydroxychloroquine (HCQ)-associated adverse events (AEs), addressing gaps in age-stratified risk assessment. METHODS: Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull modelling were applied to compare AE signals and time-to-onset profiles between paediatric (≤18 years; n = 1744) and geriatric (≥60 years; n = 14 115) populations from 22 249 476 HCQ-related reports. RESULTS: Paediatric AEs exhibited significantly earlier onset (median 9.5 days vs. 19 days). Ten novel paediatric-specific signals were identified, including COVID-19-related cardiotoxicity (ROR = 3.26, 95% confidence interval [CI] 1.87-6.94) and hypokalaemia complications (ROR = 25.77, 95% CI 18.7-35.52), with distinct reporting patterns compared to geriatric cohorts. Weibull shape parameters revealed divergent risk trajectories: constant hazard profiles in children (α = 0.52, β = 46.68) contrasted with escalating risks in older adults (α = 0.40, β = 93.66), suggesting mechanistic differences in toxicity progression. CONCLUSIONS: Significant age-related variations in HCQ-associated AE profiles, temporal dynamics and risk evolution underscore the necessity for age-stratified pharmacovigilance frameworks. Paediatric-specific cardiotoxic and metabolic risks, coupled with geriatric-specific cumulative toxicity patterns, mandate tailored therapeutic monitoring strategies to optimize safety across age extremes.
引用
- Sun G, Yang J, Wan L, et al. Age-related differences in hydroxychloroquine-associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System. Br J Clin Pharmacol. 2025. PMID: 41067279. doi:10.1002/bcp.70293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。